[New directions in contemporary pharmacotherapy of parkinsonism (review)].
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000008:administration & dosage; D001058:Apomorphine / Q000627:therapeutic use; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008090:Lisuride / Q000627:therapeutic use; D010096:Oxprenolol / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D010889:Piracetam / Q000627:therapeutic use; D010891:Piribedil / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D014151:Anti-Anxiety Agents; D000978:Antiparkinson Agents; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001971:Bromocriptine; D007980:Levodopa; D010096:Oxprenolol; D005680:gamma-Aminobutyric Acid; D011433:Propranolol; D010891:Piribedil; D008090:Lisuride; D001058:Apomorphine; D010889:Piracetam
Novye napravleniia v sovremennoĭ farmakoterapii parkinsonizma (obzor).